Quick Win By The Algorithm:

On November 21st, 2017, I Know First issued a bullish 3-days forecast for Celsion Corporation (NASDAQ: CLSN). The forecast showed a signal of 14.84 and a predictability of 0.08. In accordance with the forecast, CLSN’s stock returned 52.34% over this period, solidifying another quick win by the I Know First algorithm.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Celsion Corporation released on November 14th, 2017 its financial results for the quarter and nine month period ended September 30, 2017. The company also provided an update on its development programs for ThermoDox, which is a treatment of primary liver cancer. According to the Chairman, President and CEO, Michael Tardugno, the company is “extremely pleased with the meaningful developments” in their lead clinical programs.

Regarding the financial results, the company has shown certain improvements. For the quarter ended September 30, 2017, Celsion reported a net loss of $5.7 million, or $(0.70) per share. In comparison with the same period from the previous year, when it had a net loss of $6.4 million, or $(3.22) per share, the company’s net loss results improved around 10%.

For the nine month period ended September 30, 2017, CLSN reported a net loss of $16.1 million, or $(3.04) per share, which also improved from the $16.7 million, or $(9.27), in the same period last year.

Moreover, CLSN operating expenses decreased from $5.6 million in the third quarter of 2016 to $4.4 million in the same period this year. This was primarily due to a tighter clinical development focus coupled with lower general and administrative costs and interest expenses.

In addition, research and development costs also decreased from $4.2 million in the third quarter of 2016 to $3.3 million in the third quarter of 2017. In the nine month period, those costs decreased from $11 million in 2016 to $9.9 million this year.

Current I Know First subscribers received this bullish CLSN forecast on November 21 st, 2017. 

Disclaimer

Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.